Related Experiment Video

Updated: May 9, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

CDK2 Inhibition and Eradication of Aneuploid Cancers: Promise Meets Resistance

Samuel C Okpechi1, Zibo Chen1, Liliya Tyutyunyk-Massey1

  • 1Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.

Molecular Cancer Therapeutics
|May 8, 2026
PubMed

Insights

Targeting cyclin dependent kinase 2 (CDK2) with inhibitors can eliminate aneuploid cancers. However, a resistant polyploid cell population persists, necessitating combination therapies with CDK1 or KIF antagonists for complete eradication.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Therapeutics

Background:

  • Aneuploidy is a key characteristic of cancer, contributing to drug resistance and tumor aggressiveness.
  • Cyclin dependent kinase 2 (CDK2) inhibition offers a therapeutic strategy by inducing anaphase catastrophe in aneuploid cancer cells.
  • A subset of polyploid cancer cells exhibits resistance to CDK2 inhibition, posing a challenge for complete tumor eradication.

Purpose of the Study:

  • To investigate the mechanisms of resistance to CDK2 inhibition in aneuploid cancers.
  • To identify therapeutic strategies to overcome the resistance conferred by polyploid cancer cells.
  • To explore combination therapies involving CDK2 inhibition for enhanced anti-cancer effects.

Main Methods:

  • Review of existing literature on aneuploidy, CDK2 inhibition, and cancer drug resistance.
  • Isolation and characterization of apoptosis-resistant polyploid cancer cells.
  • In vitro and in vivo studies evaluating combination therapies.

Main Results:

  • CDK2 inhibition effectively targets aneuploid cancers through anaphase catastrophe, sparing normal cells.
  • A persistent population of polyploid cancer cells demonstrates resistance to CDK2 inhibition-induced apoptosis.
  • These resistant cells are enriched for cyclin dependent kinase 1 (CDK1) and Kinesin superfamily proteins (KIFs).

Conclusions:

  • Combination therapy with CDK2 inhibitors and antagonists of CDK1 or KIFs shows promise for eradicating both aneuploid and polyploid cancer cells.
  • This combined approach may overcome clinical drug resistance associated with aneuploidy.
  • Further clinical trials are warranted to validate this therapeutic strategy.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...